Generic drugmaker Mylan NV, citing media speculation that Teva Pharmaceutical Industries Ltd might be eyeing it as a takeover target, says it doubts that regulators would approve such a deal and is committed to its current strategy as a stand-alone company.
In a news release on Friday, Mylan said that it has not received an offer and described the idea that Teva might want to buy it as a rumor.
The Dutch company said anti-trust regulators would probably not approve a deal between Mylan and Teva, because their businesses overlap in major ways. It said it would thoroughly examine an offer if it received one.
Teva did not immediately respond to a request for comment.
Shares of Mylan rose US$2.98, or 4.5 percent, to US$69.82. Earlier they spiked up as much as 8.7 percent. Teva Pharmaceutical shares gained US$1.42, or 2.2 percent, to US$64.91.
Earlier this month, Mylan offered to buy generic drug and ingredients maker Perrigo Co for about US$29 billion, or US$205 per share. Perrigo, which is based in Ireland, said it would review Mylan’s offer. Mylan says the companies would have US$15.3 billion in combined revenue this year.
Teva has about US$20 billion in annual revenue, and its executives have spoken recently about their interest in making new acquisitions and consolidating some of the largest companies in the generic drug industry.
“We are ready to take on a transaction,” Teva head of generics business Sigurdur Olafsson said at a healthcare conference last month.
In a research note written earlier this month, Barclays analyst Douglas Tsao said Teva believes that some of the largest generic drug companies should combine their businesses, because they could save a lot of money by merging their manufacturing operations.
He said an acquisition of Mylan would “re-establish Teva as the dominant market leader.”
Teva gets almost half of its revenue from generic drugs. It also makes drugs for central nervous system disorders, respiratory illnesses and cancer, as well as over-the-counter medicines. Its biggest-selling product is the multiple sclerosis drug Copaxone. Last month, it agreed to buy Auspex Pharmaceuticals Inc, which is developing central nervous system disorder treatments, for US$3.2 billion.
Mylan shares are up 17 percent since April 7, the day before it went public with its offer for Perrigo, and are near an all-time high.
GROWING OWINGS: While Luxembourg and China swapped the top three spots, the US continued to be the largest exposure for Taiwan for the 41st consecutive quarter The US remained the largest debtor nation to Taiwan’s banking sector for the 41st consecutive quarter at the end of September, after local banks’ exposure to the US market rose more than 2 percent from three months earlier, the central bank said. Exposure to the US increased to US$198.896 billion, up US$4.026 billion, or 2.07 percent, from US$194.87 billion in the previous quarter, data released by the central bank showed on Friday. Of the increase, about US$1.4 billion came from banks’ investments in securitized products and interbank loans in the US, while another US$2.6 billion stemmed from trust assets, including mutual funds,
AI TALENT: No financial details were released about the deal, in which top Groq executives, including its CEO, would join Nvidia to help advance the technology Nvidia Corp has agreed to a licensing deal with artificial intelligence (AI) start-up Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. The world’s largest publicly traded company has paid for the right to use Groq’s technology and is to integrate its chip design into future products. Some of the start-up’s executives are leaving to join Nvidia to help with that effort, the companies said. Groq would continue as an independent company with a new chief executive, it said on Wednesday in a post on its Web
Even as the US is embarked on a bitter rivalry with China over the deployment of artificial intelligence (AI), Chinese technology is quietly making inroads into the US market. Despite considerable geopolitical tensions, Chinese open-source AI models are winning over a growing number of programmers and companies in the US. These are different from the closed generative AI models that have become household names — ChatGPT-maker OpenAI or Google’s Gemini — whose inner workings are fiercely protected. In contrast, “open” models offered by many Chinese rivals, from Alibaba (阿里巴巴) to DeepSeek (深度求索), allow programmers to customize parts of the software to suit their
JOINT EFFORTS: MediaTek would partner with Denso to develop custom chips to support the car-part specialist company’s driver-assist systems in an expanding market MediaTek Inc (聯發科), the world’s largest mobile phone chip designer, yesterday said it is working closely with Japan’s Denso Corp to build a custom automotive system-on-chip (SoC) solution tailored for advanced driver-assistance systems and cockpit systems, adding another customer to its new application-specific IC (ASIC) business. This effort merges Denso’s automotive-grade safety expertise and deep vehicle integration with MediaTek’s technologies cultivated through the development of Media- Tek’s Dimensity AX, leveraging efficient, high-performance SoCs and artificial intelligence (AI) capabilities to offer a scalable, production-ready platform for next-generation driver assistance, the company said in a statement yesterday. “Through this collaboration, we are bringing two
RSS